Validation and optimization of AFP-based biomarker panels for early HCC detection in Latin America and Europe
Authors:
- Boris J.B. BeudekerBBBoris J.B. Beudeker
- Siyu FuSFSiyu Fu
- Domingo BalderramoDBDomingo Balderramo
- Angelo Z. MattosAMAngelo Z. Mattos
- Enrique CarreraECEnrique Carrera
- Javier DiazJDJavier Diaz
- Jhon PrietoJPJhon Prieto
- Jesus BanalesJesus Banales
- Arndt VogelArndt Vogel
- Marco ArreseMAMarco Arrese
- Jeffrey OliveiraJOJeffrey Oliveira
- Zwier M.A. GroothuisminkZGZwier M.A. Groothuismink
Open Access
- 15 September 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 7 (10)
Abstract
Background: HCC is a major cause of cancer death worldwide. Serum biomarkers such as alpha-fetoprotein (AFP), protein induced by vitamin K absence-II, and the Gender, Age, AFP-L3, AFP, Des-gamma-carboxy prothrombin (GALAD) score have been recommended for HCC surveillance. However, inconsistent recommendations in international guidelines limit their clinical utility. Methods: In this multicenter study, over 2000 patient samples were collected in 6 Latin American and 2 European countries. The performance of the GALAD score was validated in cirrhotic cases, and optimized versions were tested for early-stage HCC and prediagnostic HCC detection. Results: The GALAD score could distinguish between HCC and cirrhosis in Latin American patients with an AUC of 0.76, sensitivity of 70%, and specificity of 83% at the conventional cutoff value of −0.63. In a European cohort, GALAD had an AUC of 0.69, sensitivity of 66%, and specificity of 72%. Optimizing the score in the 2 large multicenter cohorts revealed that AFP-L3 contributed minimally to early-stage HCC detection. Thus, we developed a modified GALAD score without AFP-L3, the ASAP (age, sex, AFP, and protein induced by vitamin K absence-II), which showed promise for early-stage HCC detection upon validation. The ASAP score also identified patients with cirrhosis at high risk for advanced-stage HCC up to 15 months before diagnosis (p < 0.0001) and differentiated HCC from hemangiomas, with a specificity of 100% at 71% sensitivity. Conclusion: Our comprehensive analysis of large sample cohorts validates the GALAD score’s utility in Latin American, Spanish, and Dutch patients for early-stage HCC detection. The optimized GALAD without AFP-L3, the ASAP score, is a good alternative and shows greater promise for HCC prediction.Keywords
This publication has 21 references indexed in Scilit:
- GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic SteatohepatitisClinical Gastroenterology and Hepatology, 2020
- Risk of Cirrhosis and Hepatocellular Cancer in Patients With NAFLD and Normal Liver EnzymesHepatology, 2020
- Hepatocellular CarcinomaNew England Journal of Medicine, 2019
- GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS ScoreCancer Epidemiology, Biomarkers & Prevention, 2019
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinomaJournal of Hepatology, 2018
- Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysisGastroenterology, 2018
- Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver DiseasesHepatology, 2018
- Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in PatientsClinical Gastroenterology and Hepatology, 2016
- The Detection of Hepatocellular Carcinoma Using a Prospectively Developed and Validated Model Based on Serological BiomarkersCancer Epidemiology, Biomarkers & Prevention, 2014
- Index for rating diagnostic testsCancer, 1950